THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®

Cervical Cancer Screening

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

Note: It is critical that females who do not need annual cervical cancer screening, continue with annual appointments to obtain other appropriate preventive healthcare. Women with significant comorbidities or life-threatening illnesses may forego cervical cancer screening. This algorithm is not intended for women with a personal history of cervical cancer[1].



[1] See the Cervical Cancer treatment or survivorship algorithms for the management of women with a personal history of cervical cancer.
[2] Women with certain risk factors: Diethylstilbestrol exposure (DES) in utero, immunosuppression [*e.g.*, Human Immunodeficiency Virus (HIV), organ transplant on immunosuppressive therapy], should continue to be screened annually. Women with HIV should have cervical cytology screening twice in the first year after diagnosis and then annually.
[3] Women treated in the past for cervical intraepithelial neoplasia (CIN) 2/3 or invasive cervical cancer require routine screening for at least 20 years.
[4] Women with no history of CIN 2/3 in the past 20 years should discontinue cervical cancer screening if they have had 3 negative Pap tests or 2 negative Pap and HPV tests in the past 10 years.
[5] Women with supracervical hysterectomies should follow the guidelines as for women without a hysterectomy.
[6] If screening is stopped, it should not be restarted due to new sexual contact.
[7] American Society for Colposcopy and Cervical Pathology (ASCCP) 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Screening Tests and Cancer Precursors.
Note: Women who have received the HPV vaccine should continue to be screened according to the above guideline.

Department of Clinical Effectiveness V6
Approved by the Executive Committee of the Medical Staff 02/28/2017

SUGGESTED READINGS

ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists. Number 131, Nov 2012.

Massad, L. S., Einstein, M. H., Huh, W. K., Katki, H. A., Kinney, W. K., & Schiffman, M. (2012). ASCCP Consensus Guidelines Conference. (2013). 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. *Obstetrics and Gynecology, 121*(4), 829-846. doi:10.1097/AOG.0b013e3182883a34

Leinonen, M., Nieminen, P., Kotaniemi-Talonen, L., Malila, N., Tarkkanen, J., Laurila, P., & Anttila, A. (2009). Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. *Journal of the National Cancer Institute, 101*(23), 1612-1623. doi:10.1093/jnci/djp367

Mayrand, M., Duarte-Franco, E., Rodrigues, I., Walter, S. D., Hanley, J., Ferenczy, A., . . . Canadian Cervical Cancer Screening Trial Study Group. (2007). Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. *The New England Journal of Medicine, 357*(16), 1579-1588. doi:10.1056/NEJMoa071430

Moyer, V. A., US Preventive Serv Task Force, & U.S. Preventive Services Task Force. (2012). Screening for cervical cancer: U.S. preventive services task force recommendation statement. *Annals of Internal Medicine, 156*(12), 880-891. doi:10.7326/0003-4819-156-12-201206190-00424

National Comprehensive Cancer Network. (2012). Cervical Cancer Screening. Retrieved from http://www.nccn.org/professionals/physician_gls/pdf/cervical_screening.pdf

Ogilvie, G. S., Dirk J van Niekerk, Krajden, M., Martin, R. E., Ehlen, T. G., Ceballos, K., . . . Coldman, A. J. (2010). A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: Trial design and preliminary results (HPV FOCAL trial). *BMC Cancer, 10*, 111. doi:10.1186/1471-2407-10-111

Ronco, G., New Technologies Cervical Canc Scr, & New Technologies for Cervical Cancer screening (NTCC) Working Group. (2010). Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. *Lancet Oncol, 11*(3), 249-257. doi:10.1016/S1470-2045(09)70360-2

Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J., . . . ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. (2012). American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. *CA: A Cancer Journal for Clinicians, 62*(3), 147-172. doi:10.3322/caac.21139

Schiffman, M., & Solomon, D. (2009). Screening and prevention methods for cervical cancer. *JAMA: The Journal of the American Medical Association, 302*(16), 1809-1810. doi:10.1001/jama.2009.1573

Vesco, K. K., Whitlock, E. P., Eder, M., Burda, B. U., Senger, C. A., & Lutz, K. (2011). Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the US Preventive Services Task Force. *Annals of internal medicine*, *155*(10), 698.

Whitlock, E. P., Vesco, K. K., Eder, M., Lin, J. S., Senger, C. A., & Burda, B. U. (2011). Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: A systematic review for the U.S. preventive services task force. *Annals of Internal Medicine, 155*(10), 687-W214. doi:10.7326/0003-4819-155-10-201111150-00376

Wright Jr, T., 2006 Amer Soc Colposcopy Cervical Pathol, & 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. (2007). 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. *Am J Obstet Gynecol, 197*(4), 346-355. doi:10.1016/j.ajog.2007.07.047.

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This screening algorithm is based on majority expert opinion of the Cervical Cancer Screening work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Therese Bevers, MD[Ŧ]
Powel Brown, MD
Brenda Chavez, RN, APRN, BSN, NP, TNCC
Elise Cook, MD[Ŧ]
Robin Coyne, RN, FNP
Joyce E. Dains, MD, PH, JD, RN, FNP-BC[Ŧ]
Suzanne Day, RN, FNP
Ernest Hawk, MD
Tiffany Jackson, RN, FNP
Mona King, RN, FNP, APRN
Marita Lazzaro, RN, FNP, APNP, RNCW, WHNP[Ŧ]
Karen Lu, MD
Andrea Milbourne, MD[Ŧ]
Michaelle Moise, RN, MPH, MSN, BSN, BS, FNP, NPCF
Ana Nelson, RN, FNP
Lonzetta Newman, MD
Tilu Ninan, RN, FNP
Lois M. Ramondetta, MD[Ŧ]
Kathleen Schmeler, MD[Ŧ]
Gloria Trowbridge, BSN, RN[♦]
Tralynn Victorian, RN, FNP
Anita M. Williams, BS[♦]

[Ŧ]Core Development Team
[♦]Clinical Effectiveness Development Team